Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 11 April 2017, 11:42 HKT/SGT
Share:
    

Source: Eisai
Eisai to Launch "Chocola BB Gold Rich" Highest Combination of Active Ingredients in Chocola BB Series
Easy to Drink Bergamot Flavor

TOKYO, Apr 11, 2017 - (JCN Newswire) - Eisai Co., Ltd. announced today that, approaching the 65th anniversary of its Chocola BB brand, it will launch Chocola BB Gold Rich (designated quasi-drug), a supplement drink recommended to relieve fatigue, on Monday, April 17. Chocola BB Gold Rich is a luxurious combination of 16 active ingredients, the highest number in the Chocola BB series. It contains active ingredients including B-complex vitamins and taurine 1500mg to help a fatigued body produce energy, and six natural herbs carefully selected by female developers to please female consumers, including angelica acutiloba, ginseng, and royal jelly. The bergamot orange flavor, which is also used in Earl Grey tea and other products, is easy to drink, and the gold and pink packaging is elegantly designed to give off a sense of luxury. This boxed supplement drink from the Chocola BB brand has been designed to be approachable for female consumers.

In recent years, along with the increasing social advancement of women, the market catering to female supplement drink consumers is also growing. Additionally, consumers drink different products depending on their level of fatigue. This product is designed to respond to the needs of women who want a high performance drink. Chocola BB Gold Rich is a speedy fatigue reliever perfect for busy women in the office or at home.

The Chocola BB supplement drink series includes Chocola BB Light 2 for day-to-day fatigue, Chocola BB Royal 2 for extreme fatigue, and Chocola BB Hyper for weak constitutions, all of which are marketed as designated quasi-drug products designed to help relieve fatigue.

Through the Chocola BB brand, Eisai will continue to respond to the diverse needs of female consumers and support an ever-growing number of people to achieve health and beauty in their everyday lives.


About Eisai

Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120



Apr 11, 2017 11:42 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: HealthCare
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2017 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


Multimedia
Chocola BB Gold Rich
View Image
 

Eisai
Apr 19, 2017 12:21 HKT/SGT
Eisai Announces Results and Continued Support of Initiatives for Elimination of Lymphatic Filariasis
Apr 5, 2017 10:23 HKT/SGT
Eisai and Meiji Enter Into Licensing Agreement Concerning Parkinson's Disease Drug Safinamide in Japan and Asia
Apr 5, 2017 10:12 HKT/SGT
Eisai Presents Data of Mechanisms of Action Relating to Tumor Immune Response Regarding Combination of Anticancer Agent Lenvatinib With Anti-PD-1 Antibody at AACR 108th Annual Meeting
Apr 4, 2017 08:56 HKT/SGT
Eisai to Launch Smell Identification Test UPSIT Series in Japan
Mar 29, 2017 10:09 HKT/SGT
Enrollment Commences in Phase III Clinical Study of Eisai's Bace Inhibitor Elenbecestat in Early Alzheimer's Disease in Japan
Mar 29, 2017 09:08 HKT/SGT
German Federal Joint Committee (G-Ba) Confirms Additional Benefit of Anticancer Agent Kisplyx (Lenvatinib Mesylate) in Treatment of Advanced Renal Cell Carcinoma
Jan 25, 2017 07:59 HKT/SGT
Phase III Trial of Anticancer Agent Lenvima as First-Line Treatment for Unresectable Hepatocellular Carcinoma Meets Primary Endpoint
Jan 24, 2017 17:43 HKT/SGT
Eisai Selected for Excellence in Sustainability Performance and Industry Mover Distinction by Robecosam
Jan 18, 2017 13:23 HKT/SGT
Eisai to Participate in Access Accelerated, Global Partnership to Address Rise of Non-Communicable Diseases
Jan 16, 2017 08:19 HKT/SGT
Transfer of Rights to Insomia Treatment / Anaesthesia Induction Agent Flunitrazepam in Japan
More news >>
 News Alerts
Copyright © 2017 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: